Michal Dwojak

Learn More
Clinical trials with SRC family kinases (SFKs) inhibitors used alone or in a combination with anti-CD20 monoclonal antibodies (mAbs) are currently underway in the treatment of B-cell tumors. However, molecular interactions between these therapeutics have not been studied so far. A transcriptional profiling of tumor cells incubated with SFKs inhibitors(More)
Despite major therapeutic advances in chronic lymphocytic leukaemia (CLL), there is still no curative strategy and new treatment approaches with improved efficacy are urgently needed. Although showing clinical activity in CLL patients, anti-CD20 monoclonal antibodies in chemoimmunotherapeutic regimens display rather limited efficacy. Thus combinations of(More)
  • 1